ATE295180T1 - Zubereitung zur immunisierung gegen den aids- virus - Google Patents

Zubereitung zur immunisierung gegen den aids- virus

Info

Publication number
ATE295180T1
ATE295180T1 AT01976378T AT01976378T ATE295180T1 AT E295180 T1 ATE295180 T1 AT E295180T1 AT 01976378 T AT01976378 T AT 01976378T AT 01976378 T AT01976378 T AT 01976378T AT E295180 T1 ATE295180 T1 AT E295180T1
Authority
AT
Austria
Prior art keywords
immunization against
preparation
aids virus
pharmaceutical composition
composition
Prior art date
Application number
AT01976378T
Other languages
English (en)
Inventor
Jean Haensler
Francois Dalencon
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of ATE295180T1 publication Critical patent/ATE295180T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Motorcycle And Bicycle Frame (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT01976378T 2000-10-06 2001-10-08 Zubereitung zur immunisierung gegen den aids- virus ATE295180T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012808A FR2814958B1 (fr) 2000-10-06 2000-10-06 Composition vaccinale
PCT/FR2001/003096 WO2002028427A2 (fr) 2000-10-06 2001-10-08 Composition pharmaceutique pour l'immunisation contre le sida

Publications (1)

Publication Number Publication Date
ATE295180T1 true ATE295180T1 (de) 2005-05-15

Family

ID=8855083

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01976380T ATE350057T1 (de) 2000-10-06 2001-10-08 Impfstoffzusammesetzung
AT01976378T ATE295180T1 (de) 2000-10-06 2001-10-08 Zubereitung zur immunisierung gegen den aids- virus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01976380T ATE350057T1 (de) 2000-10-06 2001-10-08 Impfstoffzusammesetzung

Country Status (12)

Country Link
US (3) US20030190326A1 (de)
EP (2) EP1326636B1 (de)
AT (2) ATE350057T1 (de)
AU (2) AU2001295671A1 (de)
CA (1) CA2424836A1 (de)
CY (1) CY1105943T1 (de)
DE (2) DE60110822T2 (de)
DK (1) DK1326636T3 (de)
ES (2) ES2240526T3 (de)
FR (1) FR2814958B1 (de)
PT (2) PT1326636E (de)
WO (2) WO2002028427A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
NZ520976A (en) * 1999-11-19 2005-01-28 Csl Ltd Vaccine compositions
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
US20080044435A1 (en) * 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
ATE411054T1 (de) * 2001-08-17 2008-10-15 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CN1753687A (zh) * 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
US7927580B2 (en) * 2004-03-16 2011-04-19 Nanirx, Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
US20060287263A1 (en) * 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
FR2881050B1 (fr) * 2005-01-25 2007-02-23 Sanofi Pasteur Sa Dcchol chez les nouveaux-nes
US20060165717A1 (en) * 2005-01-25 2006-07-27 Sanofi Pasteur DCchol in newborns
KR20080030656A (ko) * 2005-07-07 2008-04-04 콜레이 파마시티컬 그룹, 인코포레이티드 암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
EP2411043B1 (de) 2009-03-23 2013-07-31 PIN Pharma, Inc. Krebsbehandlung mit immunstimulierenden hiv-tat-derivat-polypeptiden
CN105705164A (zh) 2013-10-04 2016-06-22 品诺制药公司 用于癌症治疗的免疫刺激性hiv tat衍生多肽

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
FR2781160B1 (fr) * 1998-07-03 2000-08-18 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
FR2783170B1 (fr) * 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
EP1156781B1 (de) * 1999-02-26 2005-06-08 Chiron Corporation Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
EP1212085B1 (de) * 1999-08-27 2007-10-31 INEX Pharmaceuticals Corp. Zusammensetzungen zur stimulation der zytokin sekretion und zur induktion einer immunantwort
US20050249794A1 (en) * 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1

Also Published As

Publication number Publication date
EP1326636A2 (de) 2003-07-16
CY1105943T1 (el) 2011-04-06
WO2002028427A2 (fr) 2002-04-11
US20050118188A1 (en) 2005-06-02
AU2001295671A1 (en) 2002-04-15
ES2275738T3 (es) 2007-06-16
WO2002028428A3 (fr) 2003-02-20
DE60125797T2 (de) 2007-12-06
FR2814958A1 (fr) 2002-04-12
WO2002028427A3 (fr) 2003-03-20
DE60125797D1 (de) 2007-02-15
AU2001295673A1 (en) 2002-04-15
EP1326635B1 (de) 2005-05-11
US20030190326A1 (en) 2003-10-09
FR2814958B1 (fr) 2003-03-07
US20040038922A1 (en) 2004-02-26
PT1326635E (pt) 2005-08-31
EP1326635A2 (de) 2003-07-16
EP1326636B1 (de) 2007-01-03
DE60110822D1 (de) 2005-06-16
DK1326636T3 (da) 2007-04-30
PT1326636E (pt) 2007-02-28
CA2424836A1 (en) 2002-04-11
WO2002028428A2 (fr) 2002-04-11
ATE350057T1 (de) 2007-01-15
ES2240526T3 (es) 2005-10-16
DE60110822T2 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
ATE295180T1 (de) Zubereitung zur immunisierung gegen den aids- virus
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
DK1283700T3 (da) Farmaceutiske sustained release-præparater til parenteral administration af biologisk aktive hydrofile forbindelser
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
BR0113822A (pt) Vacina
EP1485468A4 (de) Rekombinante parainfluenzavirus-expressionssysteme und impfstoffe mit aus metapneumovirus stammenden heterologen antigenen
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
HUP0203056A1 (hu) Vakcinakészítmény
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
BRPI0113155B8 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
EP1670507A4 (de) Vakzine zur behandlung und prävention von herpes simplex-virusinfektion
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
JP2006512078A5 (de)
EP1301208A4 (de) Impfstoff
ATE372129T1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
WO2002078631A3 (en) Improved conditionally replicating vectors for inhibiting viral infections
TW200509964A (en) VP1 of foot-and-mouth disease virus
WO2004031222A3 (en) Dna vaccine encoding at least two nonstructural early proteins of papillomavirus
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
DE602004025103D1 (de) Heilkräuterzusammensetzung zur Behandlung von AIDS
WO2005097179A3 (fr) Antigene tat stabilise et ses applications pour la vaccination anti-vih.
HRP20030701A2 (en) Natural antibodies active against hiv virus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1326635

Country of ref document: EP

REN Ceased due to non-payment of the annual fee